Filed by Aratana Therapeutics, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
14a-12
of the Securities Exchange Act of 1934
Subject Company: Aratana Therapeutics, Inc.
Commission File No:
001-35952
The following social media communication was made available by Aratana Therapeutics, Inc. on May 7, 2019 on Craig Toomans LinkedIn account:
The entire Aratana team has made incredible contributions over the past 8.5 years that shaped Aratana into an outstanding company. On April 26,
Aratana announced an agreement to merge with Elanco. I couldnt agree more with fellow board member and Kansas Citys business and civic leader, Irv Hockaday, when he said this proposed transaction is very strategic as it combines
Aratanas innovative therapeutics and strong access to specialty clinics with the resources of a
top-tier
animal health company. I believe Aratana is a strong example of a startup company from Kansas City
that was able to execute on its vision and generate shareholder interest in a new sector.
Important Information for Investors and Stockholders
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or
approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the
proposed transaction between Aratana Therapeutics, Inc., a Delaware corporation (Aratana) and Elanco Animal Health Incorporated, an Indiana corporation (Elanco), pursuant to the terms of that certain Agreement and Plan of
Merger, dated as of April 26, 2019, by and among Aratana, Elanco and Elanco Athens, Inc., Elanco will file with the SEC a registration statement on Form
S-4
that will include a proxy statement of Aratana
that also constitutes a prospectus of Elanco (the proxy statement/prospectus). The definitive proxy statement/prospectus will be delivered to stockholders of Aratana. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of
the registration statement and the definitive proxy statement/prospectus (when available) and other documents filed with the SEC by Elanco and Aratana through the website maintained by the SEC at
http://www.sec.gov
. Copies of the documents
filed with the SEC by Elanco will be available free of charge on Elancos internet website at
www.elanco.com
or by contacting Elancos Investor Relations Department at (317)
383-9935.
Copies
of the documents filed with the SEC by Aratana will be available free of charge on Aratanas internet website at
www.aratana.com
or by contacting Aratanas Investor Relations Department at (913)
353-1026.
Participants in the Merger Solicitation
Elanco, Aratana, their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies
in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Aratana stockholders in connection with the proposed merger and a description of their
direct and indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus when it is filed with the SEC. Information about the directors and executive officers of Elanco is set forth in its proxy statement
for its 2019 annual meeting of shareholders, which was filed with the SEC on April 3, 2019. Information about the executive officers of Aratana is set forth in its Annual Report on Form
10-K
for the year
ended December 31, 2018 which was filed with the SEC on March 13, 2019 and additional information about its executive officers and information about its directors is set forth in its proxy statement for its 2019 annual meeting of
stockholders, which was filed with the SEC on April 19, 2019.